These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 17715348)

  • 1. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
    Asuni AA; Boutajangout A; Quartermain D; Sigurdsson EM
    J Neurosci; 2007 Aug; 27(34):9115-29. PubMed ID: 17715348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model.
    Boutajangout A; Quartermain D; Sigurdsson EM
    J Neurosci; 2010 Dec; 30(49):16559-66. PubMed ID: 21147995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
    Boutajangout A; Ingadottir J; Davies P; Sigurdsson EM
    J Neurochem; 2011 Aug; 118(4):658-67. PubMed ID: 21644996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.
    Sigurdsson EM
    J Alzheimers Dis; 2008 Oct; 15(2):157-68. PubMed ID: 18953105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
    Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
    Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
    Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
    J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous tau aggregates in oligodendrocytes of rTg4510 mice induced by human P301L tau.
    Ren Y; Lin WL; Sanchez L; Ceballos C; Polydoro M; Spires-Jones TL; Hyman BT; Dickson DW; Sahara N
    J Alzheimers Dis; 2014; 38(3):589-600. PubMed ID: 24028867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.
    Vitale F; Giliberto L; Ruiz S; Steslow K; Marambaud P; d'Abramo C
    Acta Neuropathol Commun; 2018 Aug; 6(1):82. PubMed ID: 30134961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
    Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
    J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
    Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT
    Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy.
    Köhler C; Bista P; Götz J; Schröder H
    Brain Res; 2010 Aug; 1347():111-24. PubMed ID: 20513372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.
    Strang KH; Goodwin MS; Riffe C; Moore BD; Chakrabarty P; Levites Y; Golde TE; Giasson BI
    Acta Neuropathol Commun; 2017 Jul; 5(1):58. PubMed ID: 28760159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
    Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
    J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders.
    Spencer B; Brüschweiler S; Sealey-Cardona M; Rockenstein E; Adame A; Florio J; Mante M; Trinh I; Rissman RA; Konrat R; Masliah E
    Acta Neuropathol; 2018 Jul; 136(1):69-87. PubMed ID: 29934874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser
    van Ameijde J; Crespo R; Janson R; Juraszek J; Siregar B; Verveen H; Sprengers I; Nahar T; Hoozemans JJ; Steinbacher S; Willems R; Delbroek L; Borgers M; Dockx K; Van Kolen K; Mercken M; Pascual G; Koudstaal W; Apetri A
    Acta Neuropathol Commun; 2018 Jul; 6(1):59. PubMed ID: 30001207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.
    Sigurdsson EM
    Curr Alzheimer Res; 2009 Oct; 6(5):446-50. PubMed ID: 19874269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.
    Nisbet RM; Van der Jeugd A; Leinenga G; Evans HT; Janowicz PW; Götz J
    Brain; 2017 May; 140(5):1220-1230. PubMed ID: 28379300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperactivity with Agitative-Like Behavior in a Mouse Tauopathy Model.
    Jul P; Volbracht C; de Jong IE; Helboe L; Elvang AB; Pedersen JT
    J Alzheimers Dis; 2016; 49(3):783-95. PubMed ID: 26519432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.